In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings,…
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression…
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active…
Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatmentsHighlighted…
A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's fundraising and advances…
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern from a phase 2 study…
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)…
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire…
Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions,…
Major Regulatory Milestone: The first Canadian-developed AI for ICH triage receives FDA clearance to enter the U.S. market.Operational Value: Automates…